Core Viewpoint - Invivyd, Inc. has successfully closed a public offering of 89,234,480 shares of common stock, raising approximately $57.5 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The offering included the full exercise of an underwriter's option to purchase an additional 14,423,076 shares at a public offering price of $0.52 per share [1]. - Pre-funded warrants to purchase 21,342,442 shares were also included, priced at $0.5199 each, which reflects the common stock price minus a nominal exercise price [1]. - Cantor Fitzgerald acted as the sole book-running manager for the offering, with RA Capital Management and Janus Henderson Investors leading the financing [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for trial protocol development and advancement of the VYD2311 clinical program [3]. - Funds will also support research and development for pipeline programs targeting respiratory syncytial virus (RSV) and measles, as well as efforts related to monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome [3]. - Additional uses include working capital and other general corporate purposes [3]. Group 3: Company Background - Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2 [7]. - The company employs a proprietary integrated technology platform designed to develop and adapt high-quality antibodies [7]. - In March 2024, Invivyd received emergency use authorization from the U.S. FDA for a monoclonal antibody in its innovative pipeline [7].